Morschhauser, F., Qualls, D., Lue, J., Stathis, A., Nijland, M., Kallam, A., Bittenbring, J., Cartron, G., Lang, N., Poel, M. V. D., Ysebaert, L., Vucinic, V., Garcia-Sancho, A. M., Dominguez, A. R., Purroy, N., Moucheron, B. D., Li, X., Guarinos, C., Burnett, J., Rondán, A. B., Pourdehnad, M., Voetsch, J., Sobradillo, D., Michot, J. (2025). BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study. Blood. https://doi.org/10.1182/blood-2025-480